|
|
|
COPD Clinical Trials |
|
Thank you for your interest in clinical trials for COPD.
Please click "Search" to find COPD clinical trials and medical research studies or read below for information on COPD diagnosis and treatment.
If you receive too many study listings you may enter your zip code to find the locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
|
|
Your search returned 17 studies:
|
|
|
|
|
Results from other databases:
|
|
Your search returned over 250 results. The top 250 results are being displayed. Please use
additional keywords or decrease the search distance. |
|
Your search returned 250 studies:
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-02747
Conditions: Chronic Obstructive Pulmonary Disease
Location: North Dartmouth, MA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-02780
Conditions: Chronic Obstructive Pulmonary Disease
Location: Taunton, MA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-02906
Conditions: Chronic Obstructive Pulmonary Disease
Location: Providence, RI
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-02914
Conditions: Chronic Obstructive Pulmonary Disease
Location: East Providence, RI
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-08558
Conditions: Chronic Obstructive Pulmonary Disease
Location: Skillman, NJ
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-13760
Conditions: Chronic Obstructive Pulmonary Disease
Location: Endwell, NY
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-19115
Conditions: Chronic Obstructive Pulmonary Disease
Location: Philadelphia, PA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-19335
Conditions: Chronic Obstructive Pulmonary Disease
Location: Downingtown, PA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-20902
Conditions: Chronic Obstructive Pulmonary Disease
Location: Wheaton, MD
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-21044
Conditions: Chronic Obstructive Pulmonary Disease
Location: Columbia, MD
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-22908
Conditions: Chronic Obstructive Pulmonary Disease
Location: Charlottesville, VA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-28207
Conditions: Chronic Obstructive Pulmonary Disease
Location: Charlotte, NC
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-29406
Conditions: Chronic Obstructive Pulmonary Disease
Location: North Charleston, SC
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-30096
Conditions: Chronic Obstructive Pulmonary Disease
Location: Duluth, GA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-30322
Conditions: Chronic Obstructive Pulmonary Disease
Location: Atlanta, GA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-30513
Conditions: Chronic Obstructive Pulmonary Disease
Location: Blue Ridge, GA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-32405
Conditions: Chronic Obstructive Pulmonary Disease
Location: Panama City, FL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-32720
Conditions: Chronic Obstructive Pulmonary Disease
Location: DeLand, FL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-32789
Conditions: Chronic Obstructive Pulmonary Disease
Location: Winter Park, FL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-33140
Conditions: Chronic Obstructive Pulmonary Disease
Location: Miami Beach, FL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-33186
Conditions: Chronic Obstructive Pulmonary Disease
Location: Miami, FL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-33316
Conditions: Chronic Obstructive Pulmonary Disease
Location: Ft. Lauderdale, FL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-33606
Conditions: Chronic Obstructive Pulmonary Disease
Location: Tampa, FL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-34471
Conditions: Chronic Obstructive Pulmonary Disease
Location: Ocala, FL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-35249
Conditions: Chronic Obstructive Pulmonary Disease
Location: Birmingham, AL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-36117
Conditions: Chronic Obstructive Pulmonary Disease
Location: Montgomery, AL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-36608
Conditions: Chronic Obstructive Pulmonary Disease
Location: Mobile, AL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-40215
Conditions: Chronic Obstructive Pulmonary Disease
Location: Louisville, KY
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-41017A
Conditions: Chronic Obstructive Pulmonary Disease
Location: Crestview Hills, KY
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-41017B
Conditions: Chronic Obstructive Pulmonary Disease
Location: Crescent Springs, KY
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-41701
Conditions: Chronic Obstructive Pulmonary Disease
Location: Hazard, KY
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-43560
Conditions: Chronic Obstructive Pulmonary Disease
Location: Sylvania, OH
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-43614
Conditions: Chronic Obstructive Pulmonary Disease
Location: Toledo, OH
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-45245
Conditions: Chronic Obstructive Pulmonary Disease
Location: Cincinnati, OH
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-46383
Conditions: Chronic Obstructive Pulmonary Disease
Location: Valparaiso, IN
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-47150
Conditions: Chronic Obstructive Pulmonary Disease
Location: New Albany, IN
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-51503
Conditions: Chronic Obstructive Pulmonary Disease
Location: Council Bluffs, IA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-52240
Conditions: Chronic Obstructive Pulmonary Disease
Location: Iowa City, IA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-53209
Conditions: Chronic Obstructive Pulmonary Disease
Location: Milwaukee, WI
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-55402
Conditions: Chronic Obstructive Pulmonary Disease
Location: Minneapolis, MN
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-59718
Conditions: Chronic Obstructive Pulmonary Disease
Location: Bozeman, MT
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-60076
Conditions: Chronic Obstructive Pulmonary Disease
Location: Skokie, IL
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-63122
Conditions: Chronic Obstructive Pulmonary Disease
Location: St. Louis, MO
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-66216
Conditions: Chronic Obstructive Pulmonary Disease
Location: Shawnee, KS
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-68010
Conditions: Chronic Obstructive Pulmonary Disease
Location: Boys Town, ME
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-68046
Conditions: Chronic Obstructive Pulmonary Disease
Location: Papillion, NE
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-68131
Conditions: Chronic Obstructive Pulmonary Disease
Location: Omaha, NE
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-68510
Conditions: Chronic Obstructive Pulmonary Disease
Location: Lincoln, NE
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-70508
Conditions: Chronic Obstructive Pulmonary Disease
Location: Lafayette, LA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-70584
Conditions: Chronic Obstructive Pulmonary Disease
Location: Sunset, LA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-72901
Conditions: Chronic Obstructive Pulmonary Disease
Location: Fort Smith, AR
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-73103
Conditions: Chronic Obstructive Pulmonary Disease
Location: Oklahoma City, OK
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-73112
Conditions: Chronic Obstructive Pulmonary Disease
Location: Oklahoma City, OK
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-78130
Conditions: Chronic Obstructive Pulmonary Disease
Location: New Braunfels, TX
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-78229
Conditions: Chronic Obstructive Pulmonary Disease
Location: San Antonio, TX
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-78750
Conditions: Chronic Obstructive Pulmonary Disease
Location: Austin, TX
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-79902
Conditions: Chronic Obstructive Pulmonary Disease
Location: El Paso, TX
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-80907
Conditions: Chronic Obstructive Pulmonary Disease
Location: Colorado Springs, CO
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-83814
Conditions: Chronic Obstructive Pulmonary Disease
Location: Coeur D'Alene, ID
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-84604
Conditions: Chronic Obstructive Pulmonary Disease
Location: Provo, UT
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-90025
Conditions: Chronic Obstructive Pulmonary Disease
Location: Los Angeles, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-90048
Conditions: Chronic Obstructive Pulmonary Disease
Location: Los Angeles, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-90274
Conditions: Chronic Obstructive Pulmonary Disease
Location: Rolling Hills Estates, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-90712
Conditions: Chronic Obstructive Pulmonary Disease
Location: Lakewood, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-90723
Conditions: Chronic Obstructive Pulmonary Disease
Location: Paramount, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-92120
Conditions: Chronic Obstructive Pulmonary Disease
Location: San Diego, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-92506
Conditions: Chronic Obstructive Pulmonary Disease
Location: Riverside, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-92691
Conditions: Chronic Obstructive Pulmonary Disease
Location: Mission Viejo, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-92713
Conditions: Chronic Obstructive Pulmonary Disease
Location: Portland, OR
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-92801
Conditions: Chronic Obstructive Pulmonary Disease
Location: Anaheim, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-92835
Conditions: Chronic Obstructive Pulmonary Disease
Location: Fullerton, CA
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-97213
Conditions: Chronic Obstructive Pulmonary Disease
Location: Portland, OR
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-97504A
Conditions: Chronic Obstructive Pulmonary Disease
Location: Medford, OR
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-97504B
Conditions: Chronic Obstructive Pulmonary Disease
Location: Medford, OR
- 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD) - NCT00929110-98405
Conditions: Chronic Obstructive Pulmonary Disease
Location: Tacoma, WA
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-06105
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Hartford, CT
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-15213
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Pittsburgh, PA
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-19335
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Downington, PA
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-26505
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Morgantown, WV
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-28207
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Charlotte, NC
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-29303
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Spartanburg, SC
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-29340
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Gaffney, SC
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-29379
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Union, SC
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-29406
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Charleston, SC
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-29615
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Greenville, SC
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-35294
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Birmingham, AL
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-35501
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Jasper, AL
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-35630
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Florence, AL
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-36608
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Mobile, AL
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-37601
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Johnson City, TN
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-55407
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Minneapolis, MN
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-63017
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Chesterfield, MO
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-63141
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: St. Louis, MO
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-63301
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: St. Charles, MO
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-70584
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Sunset, LA
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-83814
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Coeur D'Alene, ID
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-85006
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Phoenix, AZ
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-90505
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Torrance, CA
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-92103
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: San Diego, CA
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT00857766-99204
Conditions: Cardiovascular Disease - Chronic Bronchitis - Chronic Obstructive Pulmonary Disease (COPD) - CV Risk - Emphysema - Smoking
Location: Spokane, WA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-02720
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Fall River, MA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-28207
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Charlotte, NC
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-28401
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Wilmington, NC
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-29303A
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Spartanburg, SC
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-29303B
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Spartanburg, SC
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-29340
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Gaffney, SC
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-29406
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Charleston, SC
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-29615
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Greenville, SC
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-29669
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Pelzer, SC
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-30060
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Marietta, GA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-30106
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Austell, GA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-30281
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Stockbridge, GA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-30342A
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Atlanta, GA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-30342B
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Atlanta, GA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-32405
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Panama City, FL
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-32720
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Deland, FL
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-32789
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Winter Park, FL
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-32822
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Orlando, FL
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-33321
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Tamarac, FL
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-33755
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Clearwater, FL
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-34741
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Kissimmee, FL
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-36106
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Montgomery, AL
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-36608
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Mobile, AL
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-41701
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Hazard, KY
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-42431
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Madisonville, KY
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-43215
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Columbus, OH
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-47714
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Evansville, IN
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-48152
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Livonia, MI
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-55407
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Minneapolis, MN
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-55438
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Edina, MN
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-63117
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: St. Louis, MO
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-63141
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: St. Louis, MO
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-67205
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Wichita, KS
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-67207
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Wichita, KS
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-70115
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: New Orleans, LA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-70584
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Sunset, LA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-76301
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Wichita Falls, TX
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-78229
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: San Antonio, TX
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-83814
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Coeur D'Alene, ID
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-85032
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Phoenix, AZ
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-85258
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Scottsdale, AZ
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-91343
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Sepulveda, CA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-92024
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Encinitas, CA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-92117
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: San Diego, CA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-92270
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Rancho Mirage, CA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-92506
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Riverside, CA
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01053988-97504
Conditions: Pulmonary Disease, Chronic Obstructive - Chronic Obstructive Pulmonary Disease
Location: Medford, OR
- A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium - NCT00949975-
Conditions: Chronic Obstructive Pulmonary Disease
Location: BOERNE, TX
- A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease - NCT01009424-15213
Conditions: COPD
Location: Pittsburgh, PA
- A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease - NCT01009424-19140
Conditions: COPD
Location: Philadelphia, PA
- A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease - NCT01009424-28207
Conditions: COPD
Location: Charlotte, NC
- A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease - NCT01009424-29303
Conditions: COPD
Location: Spartanburg, SC
- A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease - NCT01009424-68198
Conditions: COPD
Location: Omaha, NE
- A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease - NCT01009424-78229
Conditions: COPD
Location: San Antonio, TX
- A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease - NCT01009424-90502
Conditions: COPD
Location: Torrance, CA
- A Novel Unidirectional Face Mask During Noninvasive Positive Pressure Ventilation (NPPV) in Chronic Obstructive Pulmonary Disease (COPD) Patients - NCT00972868-02114
Conditions: Chronic Obstructive Pulmonary Disease
Location: Boston, MA
- A Registry of COPD Patients to be Used for Future Studies - NCT00814203-43210
Conditions: Chronic Obstructive Lung Disease
Location: Columbus, OH
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Gainesville, GA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-01201
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Pittsfield, MA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-02301
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Brockton, MA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-02720
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Fall River, MA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-06105
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Hartford, CT
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-07091
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Summit, NJ
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-08003
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Cherry Hill, NJ
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-12205
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Albany, NY
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-13212
Conditions: Pulmonary Disease, Chronic Obstructive
Location: North Syracuse, NY
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-23249
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Richmond, VA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-23606
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Newport News, VA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-27215
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Burlington, NC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-28207
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Charlotte, NC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-28401
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Wilmington, NC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-28625
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Statesville, NC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-28803
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Asheville, NC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-29201
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Columbia, SC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-29303
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Spartanburg, SC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-29406
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Charleston, SC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-29615
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Greenville, SC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-29640
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Easley, SC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-29669
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Pelzer, SC
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-30274
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Riverdale, GA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-30907
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Martinez, GA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-32503
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Pensacola, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-32720
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Deland, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-32789
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Winter Park, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-32927
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Cocoa, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-33183
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Miami, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-33316
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Fort Lauderdale, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-33603
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Tampa, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-33707
Conditions: Pulmonary Disease, Chronic Obstructive
Location: St. Petersburg, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-33765
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Clearwater, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-34741
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Kissimmee, FL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-35215
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Birmingham, AL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-35294
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Birmingham, AL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-36078
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Tallassee, AL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-36608
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Mobile, AL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-37232
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Nashville, TN
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-41701
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Hazard, KY
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-42431
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Madisonville, KY
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-45459
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Centerville, OH
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-47713
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Evansville, IN
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-47714
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Evansville, IN
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-49601
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Cadillac, MI
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-53715
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Madison, WI
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-55438
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Edina, MN
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-60007
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Elk Grove Village, IL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-60504
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Aurora, IL
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-63143
Conditions: Pulmonary Disease, Chronic Obstructive
Location: St. Louis, MO
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-65803
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Springfield, MO
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-66061
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Olathe, KS
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-66606
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Topeka, KS
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-68046
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Papillion, NE
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-68134
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Omaha, NE
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-68506
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Lincoln, NE
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-75110
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Corsicana, TX
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-76301
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Wichita Falls, TX
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-77030
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Houston, TX
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-78130
Conditions: Pulmonary Disease, Chronic Obstructive
Location: New Braunfels, TX
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-80233
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Thornton, CO
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-83814
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Coeur D'Alene, ID
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-85013
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Phoenix, AZ
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-85224
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Chandler, AZ
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-89106
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Las Vegas, NV
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-90015A
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Los Angeles, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-90015B
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Los Angeles, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-90502
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Torrance, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-90505
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Torrance, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-90808
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Long Beach, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-91950
Conditions: Pulmonary Disease, Chronic Obstructive
Location: National City, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-92117
Conditions: Pulmonary Disease, Chronic Obstructive
Location: San Diego, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-92128
Conditions: Pulmonary Disease, Chronic Obstructive
Location: San Diego, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-93710
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Fresno, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-93726
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Fresno, CA
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01017952-97220
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Portland, OR
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Decatur, GA
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-02919
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Johnston, RI
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-06902
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Stamford, CT
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-08736
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Manasquan, NJ
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-10004
Conditions: Pulmonary Disease, Chronic Obstructive
Location: New York, NY
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-10029
Conditions: Pulmonary Disease, Chronic Obstructive
Location: New York, NY
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-18960
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Sellersville, PA
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-22401
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Fredericksburg, VA
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-22911
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Charlottesville, VA
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-23225
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Richmond, VA
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-23455
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Virgina Beach, VA
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-24210
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Abingdon, VA
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-27909
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Elizabeth City, NC
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-28144
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Salisbury, NC
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-29340
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Gaffney, SC
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-29406
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Charleston, SC
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - NCT01009463-29621
Conditions: Pulmonary Disease, Chronic Obstructive
Location: Anderson, SC
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|